Sosei heptares' partner neurocrine biosciences initiates phase 1 clinical study evaluating effects of nbi-1117570 in healthy adults

Tokyo, japan and cambridge, uk, 12 september 2023 – sosei group corporation (“the company”; tse: 4565), has been notified by its partner neurocrine biosciences inc. (“neurocrine”; nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, that it has initiated its phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound nbi-1117570 in healthy adult participants. nbi-1117570 is an investigational, oral, muscarinic m1/m4 selective dual agonist that may have the potential to treat neurological and neuropsychiatric conditions and was developed utilising sosei heptares' structure-based drug design platform.
NBIX Ratings Summary
NBIX Quant Ranking